Evidence map›Paper›PMID 36655131›Full record

ArticleACS medicinal chemistry letters2023

Synthesis of Novel Kidney-Type Glutaminase Allosteric Inhibitors Targeting the Critical Lys-320 Residue.

Jun Song, Chuqiao Pan, Jinxiu Li, Ruisong Bai, Ziying Zeng, Yunying Han, Zhao Chen, Wei Hou, Yong Li, Benfang Helen Ruan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jun SongCollege of Pharmaceutical Science, Institute of Drug Development & Chemical Biology (IDD &CB), Collaborative Innovation Center of Yangtza River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou,310014, PR China.
Chuqiao PanCollege of Pharmaceutical Science, Institute of Drug Development & Chemical Biology (IDD &CB), Collaborative Innovation Center of Yangtza River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou,310014, PR China.
Jinxiu LiCollege of Pharmaceutical Science, Institute of Drug Development & Chemical Biology (IDD &CB), Collaborative Innovation Center of Yangtza River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou,310014, PR China.
Ruisong BaiCollege of Pharmaceutical Science, Institute of Drug Development & Chemical Biology (IDD &CB), Collaborative Innovation Center of Yangtza River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou,310014, PR China.
Ziying ZengCollege of Pharmaceutical Science, Institute of Drug Development & Chemical Biology (IDD &CB), Collaborative Innovation Center of Yangtza River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou,310014, PR China.
Yunying HanCollege of Pharmaceutical Science, Institute of Drug Development & Chemical Biology (IDD &CB), Collaborative Innovation Center of Yangtza River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou,310014, PR China.
Zhao ChenCollege of Pharmaceutical Science, Institute of Drug Development & Chemical Biology (IDD &CB), Collaborative Innovation Center of Yangtza River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou,310014, PR China.
Wei HouCollege of Pharmaceutical Science, Institute of Drug Development & Chemical Biology (IDD &CB), Collaborative Innovation Center of Yangtza River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou,310014, PR China.ORCID https://orcid.org/0000-0002-9027-8991
Yong LiCollege of Pharmaceutical Science, Institute of Drug Development & Chemical Biology (IDD &CB), Collaborative Innovation Center of Yangtza River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou,310014, PR China.
Benfang Helen RuanCollege of Pharmaceutical Science, Institute of Drug Development & Chemical Biology (IDD &CB), Collaborative Innovation Center of Yangtza River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou,310014, PR China.ORCID https://orcid.org/0000-0001-9981-8328
Zhejiang University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reversible allosteric inhibitors of kidney-type glutaminase (GLS1, KGA) showed incomplete inhibition of cancer cell proliferation and poor

Identifiers

PMID36655131
PMCPMC9841584
OpenAlexW4312193176

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.